Liza Laws, Author at Labiotech.eu

More News! 13 Jul 2022

Paradigm of treatment of mental health to be transformed by gut-brain development program

Building on a decade of research, a development program for next-generation probiotics and therapeutics to modulate gut microbiota and mental health has been launched. Seed Health, a microbiome science company along with Axial Therapeutics, a clinical stage biopharmaceutical company announced the joint program in the US today (July 13). It will build on the work […]

July 13, 2022 - 3 minutesmins - By Liza Laws

News and Trends 13 Jul 2022

First aseptic filling line and facilities completed in Taiwan

The construction of a fully-automated aseptic filling line and facilities has been finished in Taiwan. Amaran Biotechnology Inc., a subsidiary of Taiwan’s OBI Pharma Inc., made the announcement that the new facility, a first for the country, minimizes the risks of human factors affecting the quality of pharmaceutical products, and enhances their safety. The project […]

July 13, 2022 - 2 minutesmins - By Liza Laws

Patient dosed in phase 1 trial evaluating ATG-018 treatment

News and Trends 13 Jul 2022

Development of cancer therapeutics accelerated by end-to-end single-cell multi-omics services

Solid tumor assays have been launched by Mission Bio Inc., through its Pharma Assay Development (PAD) services. The availability of this new service offering from Mission Bio, a high-throughput single-cell DNA and multi-omics analysis company, will help accelerate the development of cancer therapeutics. It will do so by reducing the time and cost associated with […]

July 13, 2022 - 3 minutesmins - By Liza Laws

News and Trends 13 Jul 2022

Sanofi sells two portfolios of established products to Neuraxpharma

Two drugs portfolios with products to treat the central nervous system, pain and vascular disease have been bought by pharmaceutical company, Neuraxpharm Group. The company bought the portfolios from French healthcare company, Sanofi. Jörg-Thomas Dierks, CEO of Neuraxpharm, said: “There is significant growth potential in the pharmaceutical sector, especially in the CNS market driven […]

July 13, 2022 - 2 minutesmins - By Liza Laws

antibody drug conjugate adc small cancer treatment

News and Trends 12 Jul 2022

Legochem Bioscience signs agreement with Glycotope to develop cancer drug

A company from South Korea has signed a research collaboration and license agreement with a German business to develop a cancer fighting drug. Seoul-based Legochem Biosciences Inc and Berlin-based Glycotope GmbH will develop an antibody drug conjugate (ADC) by combining LBC’s technology with one of Glycotope’s investigational tumor targeting antibodies. ADCs are a class of […]

July 12, 2022 - 3 minutesmins - By Liza Laws

News and Trends 12 Jul 2022

Spanish company, 3P Biopharmaceuticals, manufactures biomass to treat black fungus

A biomass to treat a difficult and evasive fungal infection with a high mortality rate has been manufactured by Spanish organization, 3P Biopharmaceuticals (3P). It created BSG005 biomass for its partner and client, Biosergen, a Norwegian biotechnology company that has just announced a phase 2 clinical trial of the product against mucormycosis – also known […]

July 12, 2022 - 3 minutesmins - By Liza Laws

News and Trends 12 Jul 2022

First patient receives new immunotherapy drug for HIV in clinical trial

A new class of bispecific protein immunotherapy, being developed for patients with human immunodeficiency virus (HIV) infection, has been given to the first patient in a clinical trial. Immunocare Holdings plc, a UK-based, commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad […]

July 12, 2022 - 3 minutesmins - By Liza Laws

News and Trends 12 Jul 2022

AI being used to perform molecular analysis of biopsies from bowel disease patients

Artificial intelligence will be used to perform molecular analysis of biopsies from unidentified Inflammatory Bowel Disease (IBD) patients in a bid to help those with immune diseases and cancer. Athos Therapeutics, a late-stage preclinical, California-based biotech company uses artificial intelligence to develop small molecule therapeutics for immune-mediated diseases and cancer, announced this week (July 11) […]

July 12, 2022 - 2 minutesmins - By Liza Laws

News and Trends 11 Jul 2022

Financing round of $21M completed for drug to treat autoimmune diseases

The first-round of financing to the tune of $21 million (€20.6 million), for a drug to treat autoimmune disease, has been completed between Precision Autoimmune Therapeutics (PAT) and CASI Pharmaceuticals. PAT will pay CASI a $5 million (€4.9 million) equivalent as the first instalment of the upfront payment of the sub-license agreement. In May this […]

July 11, 2022 - 3 minutesmins - By Liza Laws

News and Trends 11 Jul 2022

Treatment for cancer-associated thrombosis fast-tracked by FDA

A clinical-stage biotechnology company that develops therapies for cardiovascular and metabolic diseases today (July 11) announced it has been granted fast track designation by the US Food and Drug Administration (FDA) for a treatment for thrombosis associated with cancer. Anthos Therapeutics focuses on the development and commercialization of drugs and abelacimab is a new, highly […]

July 11, 2022 - 4 minutesmins - By Liza Laws

beta-thalassemia blood APS antiphospholipid syndrome

News and Trends 11 Jul 2022

Study results reveal bleeding episodes are significantly reduced by hemophilia drug

People suffering from a severe blood disorder may only have to take a once-monthly drug following successful results from an ongoing study. Global healthcare company, Sanofi, has been conducting a study into fitusiran prophylaxis and results have shown it reduces bleeds by 61 per cent in people with hemophilia A or B, with or without […]

July 11, 2022 - 4 minutesmins - By Liza Laws

News and Trends 8 Jul 2022

New drug application for treatment of dry eyes disease submitted to FDA

A treatment for dry eye symptoms associated with Meibomian gland dysfunction (MGD) has been submitted under a New Drug Application (NDA) and will be considered by the US Food and Drug Administration. The application was submitted at the end of last month (June) by the Canada-based global eye health company, Bausch and Lomb Corporation, and […]

July 8, 2022 - 2 minutesmins - By Liza Laws

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Liza Laws

Articles by Liza Laws

Paradigm of treatment of mental health to be transformed by gut-brain development program

First aseptic filling line and facilities completed in Taiwan

Development of cancer therapeutics accelerated by end-to-end single-cell multi-omics services

Sanofi sells two portfolios of established products to Neuraxpharma

Legochem Bioscience signs agreement with Glycotope to develop cancer drug

Spanish company, 3P Biopharmaceuticals, manufactures biomass to treat black fungus

First patient receives new immunotherapy drug for HIV in clinical trial

AI being used to perform molecular analysis of biopsies from bowel disease patients

Financing round of $21M completed for drug to treat autoimmune diseases

Treatment for cancer-associated thrombosis fast-tracked by FDA

Study results reveal bleeding episodes are significantly reduced by hemophilia drug

New drug application for treatment of dry eyes disease submitted to FDA

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Articles by Liza Laws

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!